NEW YORK (GenomeWeb News) – Merck Canada on Thursday announced a C$2 million (US$1.8 million) grant to a Quebec entity in support of research into personalized medicine approaches for cancer.

The grant is being provided to the Quebec-Consortium de recherché en oncologie Clinique (Q-CROC), which plans to use it for biomarker-driven clinical research into cancer. In particular, Merck noted a public-private partnership put forward by Q-CROC and the new Centre of Excellence PreThera Research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.